AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6735044 — intervention group
Group type: COMPARATOR
Intervention: AAS alone
Number of subjects: 12
Study 6735044 — intervention group
Group type: EXPERIMENTAL
Intervention: AAS + Gelox
Number of subjects: 12
Study 30696977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D) 50,000 IU weekly for 3 months
Number of subjects: 48
Study 30696977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 29499584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study 29499584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27354258 — intervention group
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Number of subjects: 500
Study 27354258 — intervention group
Group type: COMPARATOR
Intervention: qHPV vaccine
Number of subjects: 500
Study 25205201 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg twice daily plus amoxicillin 1 g thrice daily for 14 days
Number of subjects: 120
Study 25205201 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 10 mg twice daily plus amoxicillin 1 g thrice daily for 14 days
Number of subjects: 120
Study 22798540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention participants (n=92) received assistance from trained kidney transplant recipients who provided tailored information and support in completing transplant process steps.
Number of subjects: 167
Study 22798540 — intervention group
Group type: COMPARATOR
Intervention: Control participants (n=75) continued to receive usual care without additional support.
Number of subjects: 167
Study 20699744 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa
Number of subjects: 2050
Study 20699744 — intervention group
Group type: COMPARATOR
Intervention: Control (no rFVIIa)
Number of subjects: 2050
Study 18171966 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty with navigation
Number of subjects: 320
Study 18171966 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty without navigation
Number of subjects: 320
Study 15830980 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoplasty (Coblation)
Number of subjects: 64
Study 15830980 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM (Coblation‐Assisted Microdiscectomy)
Number of subjects: 64
Study 12455715 — intervention group
Group type: EXPERIMENTAL
Intervention: ABPM 1
Number of subjects: 30
Study 12455715 — intervention group
Group type: EXPERIMENTAL
Intervention: ABPM 3
Number of subjects: 30
Study 12455715 — intervention group
Group type: EXPERIMENTAL
Intervention: ABPM 1, ABPM 2, ABPM 3
Number of subjects: 30
Study 10515673 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT with progestin for 10 days during 12 week cycles of estrogen (17beta‐estradiol 2 mg per day, reduced to 1 mg during last 6 days)
Number of subjects: 240
Study 10515673 — intervention group
Group type: COMPARATOR
Intervention: HRT with progestin for 10 days during monthly cycles of estrogen (17beta‐estradiol 2 mg per day, reduced to 1 mg during last 6 days)
Number of subjects: 240
Study 10515673 — intervention group
Group type: EXPERIMENTAL
Intervention: Long cycle HRT
Number of subjects: 240
Study 7640054 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ifosfamide (9 g/m2 over 72 h)
Number of subjects: 17
Study 7640054 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of ifosfamide (3 g/m2 every 24 h for 3 days)
Number of subjects: 17
Study 1904568 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg transdermal E2 patches for 2 weeks, followed by 0.1 mg patches for 4 weeks (immediate ERT)
Number of subjects: 24
Study 1904568 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg transdermal E2 patches for 2 weeks, followed by 0.1 mg patches for 4 weeks (delayed ERT)
Number of subjects: 24
Study 1904568 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg transdermal E2 patches
Number of subjects: 24
Study 7028704 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 9
Study 7028704 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 9
Study 7028704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31400356 — intervention group
Group type: EXPERIMENTAL
Intervention: MICA-A4 allele
Number of subjects: 124
Study 31400356 — intervention group
Group type: EXPERIMENTAL
Intervention: MICA*012:01 allele
Number of subjects: 124
Study 31400356 — intervention group
Group type: EXPERIMENTAL
Intervention: MICA-A5 allele
Number of subjects: 124
Study 31400356 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygote MICA*012:01/012:01
Number of subjects: 124
Study 31400356 — intervention group
Group type: EXPERIMENTAL
Intervention: MICB*008 allele
Number of subjects: 124
Study 29055056 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/d
Number of subjects: 90
Study 29055056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 29055056 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 90
Study 26695758 — intervention group
Group type: EXPERIMENTAL
Intervention: Natesto™ Testosterone Nasal Gel (11 mg b.i.d. or 11 mg t.i.d.)
Number of subjects: 306
Study 26695758 — intervention group
Group type: EXPERIMENTAL
Intervention: Natesto™ Testosterone Nasal Gel (titration arm)
Number of subjects: 306
Study 26695758 — intervention group
Group type: EXPERIMENTAL
Intervention: Natesto™ Testosterone Nasal Gel (fixed-dose arm)
Number of subjects: 306
Study 26695758 — intervention group
Group type: EXPERIMENTAL
Intervention: Natesto™ Testosterone Nasal Gel
Number of subjects: 306
Study 23474648 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein/calorie parenteral nutrition (HPC-PN)
Number of subjects: 115
Study 23474648 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard parenteral nutrition)
Number of subjects: 115
Study 23168752 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraceptive (LARC) methods (IUDs and implants) provided at no cost
Number of subjects: 9256
Study 23168752 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOICE cohort receiving no-cost contraception
Number of subjects: 9256
Study 20217117 — intervention group
Group type: EXPERIMENTAL
Intervention: E45 (90 min of exercise at 45% VO(2)peak)
Number of subjects: 18
Study 20217117 — intervention group
Group type: EXPERIMENTAL
Intervention: E65 (60 min of exercise at 65% VO(2)peak)
Number of subjects: 18
Study 20217117 — intervention group
Group type: COMPARATOR
Intervention: C (sedentary control trial)
Number of subjects: 18
Study 18029463 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-alpha (700 ng/m(2).h(1)) for 4 hours
Number of subjects: 10
Study 16624589 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG-fMRI
Number of subjects: 46
Study 12358116 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric rehabilitation in a geriatric ward
Number of subjects: 243
Study 12358116 — intervention group
Group type: COMPARATOR
Intervention: Standard care in local hospital wards
Number of subjects: 243
Study 10230190 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 16
Study 10230190 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification (BMOD)
Number of subjects: 16
Study 10230190 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 16
Study 8807354 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood and food cues (individualized high-risk/favorite foods)
Number of subjects: 15
Study 8807354 — intervention group
Group type: COMPARATOR
Intervention: Mood cues
Number of subjects: 15
Study 8807354 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk foods presentation
Number of subjects: 15
Study 8807354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue presentation
Number of subjects: 15
Study 1684704 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied tension (AT)
Number of subjects: 30
Study 1684704 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-only (T)
Number of subjects: 30
Study 1684704 — intervention group
Group type: COMPARATOR
Intervention: Exposure in vivo (E)
Number of subjects: 30
Study 6310832 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (Aza) and prednisone
Number of subjects: 122
Study 6310832 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine and prednisone
Number of subjects: 122
Study 6310832 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 122
Study 6310832 — intervention group
Group type: EXPERIMENTAL
Intervention: Aza
Number of subjects: 122
Study 6310832 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplant group
Number of subjects: 122
Study 6310832 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine patients
Number of subjects: 122
Study 30925181 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention
Number of subjects: 2329
Study 30925181 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 2329
Study 30389343 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% cyclosporin A cationic emulsion (CsA CE)
Number of subjects: 62
Study 28805670 — intervention group
Group type: EXPERIMENTAL
Intervention: Salacia Chinensis (300 mg)
Number of subjects: 48
Study 28805670 — intervention group
Group type: EXPERIMENTAL
Intervention: Salacia Chinensis (500 mg)
Number of subjects: 48
Study 28805670 — intervention group
Group type: EXPERIMENTAL
Intervention: Salacia Chinensis (300 mg) or (500 mg)
Number of subjects: 48
Study 28805670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 25623753 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous delivery of trastuzumab via Single Injectable Device (SID)
Number of subjects: 467
Study 25623753 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous delivery of trastuzumab via hand-held syringe (HHS)
Number of subjects: 467
Study 25623753 — intervention group
Group type: COMPARATOR
Intervention: Intravenous delivery of trastuzumab
Number of subjects: 467
Study 23926746 — intervention group
Group type: EXPERIMENTAL
Intervention: Roth 801 sealer mixed with a 10:1 powder/liquid ratio
Number of subjects: 152
Study 23926746 — intervention group
Group type: EXPERIMENTAL
Intervention: Roth 801 sealer mixed with a 7.5:1 powder/liquid ratio
Number of subjects: 152
Study 23926746 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 teeth)
Number of subjects: 152
Study 21406054 — intervention group
Group type: EXPERIMENTAL
Intervention: Various antiretroviral drugs
Number of subjects: 0
Study 21406054 — intervention group
Group type: EXPERIMENTAL
Intervention: Older and lesser used drugs
Number of subjects: 0
Study 21406054 — intervention group
Group type: EXPERIMENTAL
Intervention: Recently approved drugs
Number of subjects: 0
Study 21406054 — intervention group
Group type: EXPERIMENTAL
Intervention: Compounds under investigation
Number of subjects: 0
Study 18418309 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 0
Study 18418309 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 0
Study 17012641 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) enhanced exercise program
Number of subjects: 20
Study 17012641 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VR)
Number of subjects: 20
Study 14582600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual and STD/AIDS prevention program
Number of subjects: 536
Study 14582600 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 536
Study 11062273 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubeluzole
Number of subjects: 1786
Study 11062273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1786
Study 8940782 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric probe
Number of subjects: 39
Study 8940782 — intervention group
Group type: COMPARATOR
Intervention: Adult probe
Number of subjects: 39
Study 8253699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 3819
Study 8253699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3819
Study 4003573 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (0.45 M)
Number of subjects: 7
Study 4003573 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (0.15 M)
Number of subjects: 7
Study 31195890 — intervention group
Group type: EXPERIMENTAL
Intervention: MTBI group
Number of subjects: 378
Study 31195890 — intervention group
Group type: COMPARATOR
Intervention: Trauma controls
Number of subjects: 378
Study 31195890 — intervention group
Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 378
Study 31195890 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of acute HAIH
Number of subjects: 378
Study 31195890 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of persistent HAIH
Number of subjects: 378
Study 31195890 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HAIH during the first 3 months post-injury
Number of subjects: 378
Study 30019352 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO‐5
Number of subjects: 699
Study 30019352 — intervention group
Group type: EXPERIMENTAL
Intervention: BDI‐II
Number of subjects: 699
Study 30019352 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO‐5 and BDI‐II
Number of subjects: 699
Study 30019352 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 699
Study 26712182 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous aortic root and vein graft cold blood cardioplegia and continuous controlled warm blood perfusion through vein grafts during proximal ends anastomosis.
Number of subjects: 434
Study 26712182 — intervention group
Group type: COMPARATOR
Intervention: Routine aortic root antegrade cardioplegia with no warm blood perfusion during proximal anastomosis of vein grafts.
Number of subjects: 434
Study 25891543 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg daily at 10 a.m.)
Number of subjects: 3
Study 25891543 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=2) or no treatment (n=1)
Number of subjects: 3
Study 23134886 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral palsy (CP)
Number of subjects: 32
Study 23134886 — intervention group
Group type: COMPARATOR
Intervention: Typically developing children (TDC)
Number of subjects: 32
Study 23134886 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginally ambulant and nonambulant children with CP
Number of subjects: 32
Study 23134886 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonambulant children with CP
Number of subjects: 32
Study 20180938 — intervention group
Group type: EXPERIMENTAL
Intervention: New Cooperative Medical Scheme (NCMS) reimbursement
Number of subjects: 881
Study 20180938 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost control measures and other medical financial assistance (MFA)
Number of subjects: 881
Study 18284461 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 19
Study 18284461 — intervention group
Group type: COMPARATOR
Intervention: Control group (HF patients with OSA, LVEF <45%, apnoea/hypopnoea index <10/h, n = 7)
Number of subjects: 19
Study 15868252 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical GTN (5 ml, 1 mg/ml)
Number of subjects: 104
Study 11883772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus 22 Double Array (basal array)
Number of subjects: 6
Study 11883772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus 22 Double Array (both arrays)
Number of subjects: 6
Study 11883772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus 22 Double Array (apical array)
Number of subjects: 6
Study 10401947 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiron M865 lactate analyzer
Number of subjects: 17
Study 10401947 — intervention group
Group type: COMPARATOR
Intervention: YSI mode 2300 lactate/glucose analyzer
Number of subjects: 17
Study 10401947 — intervention group
Group type: COMPARATOR
Intervention: Hitachi 911 lactate/glucose/electrolyte/enzyme analyzer
Number of subjects: 17
Study 10401947 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiron M865
Number of subjects: 17
Study 7726425 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 45 mg and epinephrine 15 micrograms (Group 5)
Number of subjects: 50
Study 7726425 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group 1)
Number of subjects: 50
Study 7726425 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 45 mg (Group 2)
Number of subjects: 50
Study 7726425 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 45 mg and epinephrine 5 micrograms (Group 3)
Number of subjects: 50
Study 7726425 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 45 mg and epinephrine 10 micrograms (Group 4)
Number of subjects: 50
Study 2029201 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term administration group (L) receiving Cyclophosphamide (CPA) at a total dose of 25 g/m2 over 18 months
Number of subjects: 308
Study 2029201 — intervention group
Group type: COMPARATOR
Intervention: Short-term administration group (S) receiving Cyclophosphamide (CPA) at a total dose of 6 g/m2 over 6 months
Number of subjects: 308
Study 2029201 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term administration group (L)
Number of subjects: 308
Study 117442 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative parenteral nutrition over a 7-10 day period
Number of subjects: 74
Study 117442 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study 29420227 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 7.5 mg/kg, 5 days/week for 4 weeks and 3 days/week for another 4 weeks with metronidazole 20 mg/kg/day for 8 weeks (group 1)
Number of subjects: 73
Study 29420227 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole alone for 8 weeks (group 2)
Number of subjects: 73
Study 29420227 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label azithromycin for failures in group 2
Number of subjects: 73
Study 28194668 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw rhubarb solution (250 cases drank a raw rhubarb soak solution per 3 hours until defecation after ERCP)
Number of subjects: 500
Study 28194668 — intervention group
Group type: COMPARATOR
Intervention: Water (control group, 250 cases drank water after ERCP)
Number of subjects: 500
Study 28194668 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw rhubarb solution
Number of subjects: 500
Study 28194668 — intervention group
Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 500
Study 25528692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial serving size recommendation on large pack
Number of subjects: 730
Study 25528692 — intervention group
Group type: COMPARATOR
Intervention: Non-pictorial serving size recommendation
Number of subjects: 730
Study 25528692 — intervention group
Group type: EXPERIMENTAL
Intervention: Serving size recommendation (pictorial) in lab experiment
Number of subjects: 730
Study 25528692 — intervention group
Group type: COMPARATOR
Intervention: No serving size recommendation in lab experiment
Number of subjects: 730
Study 23499064 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX implant 0.7 mg
Number of subjects: 329
Study 23499064 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 329
Study 17215530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 903
Study 17215530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 903
Study 17215530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 903
Study 14764781 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone application (Virormone, 5 mg) for 8 or 12 hours
Number of subjects: 8
Study 10833890 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine 40 mg alone in the morning
Number of subjects: 50
Study 10833890 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine 40 mg in combination with melatonin 3 mg overnight
Number of subjects: 50
Study 9752921 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration
Number of subjects: 0
Study 9752921 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration and injection of steroid
Number of subjects: 0
Study 9752921 — intervention group
Group type: COMPARATOR
Intervention: Aspiration (control group)
Number of subjects: 0
Study 8411611 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg in the morning
Number of subjects: 43
Study 8411611 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice a day
Number of subjects: 43
Study 8411611 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (crossover to Omeprazole)
Number of subjects: 43
Study 3085212 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin, 12.5 mg/kg body weight, administered orally 30-240 min before surgery
Number of subjects: 33
Study 30199744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 10
Study 28651550 — intervention group
Group type: EXPERIMENTAL
Intervention: C3 (2 mg/mL) applied four times daily for 2 weeks
Number of subjects: 30
Study 28651550 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (water) applied to upper eyelids
Number of subjects: 30
Study 27487640 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 120
Study 27487640 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal acetaminophen
Number of subjects: 120
Study 27487640 — intervention group
Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 120
Study 27487640 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 120
Study 23572477 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating and Exercise Lifestyle Program (HEELP)
Number of subjects: 147
Study 23572477 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 147
Study 21819308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cords at room temperature (CR)
Number of subjects: 80
Study 21819308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cords stored on ice (CI)
Number of subjects: 80
Study 21819308 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringes at room temperature (SR)
Number of subjects: 80